Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the “Cellular Therapy in the Asia Pacific Region” Session at the ...
February 04 2020 - 9:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global
developer of cell-based technologies and therapeutics, announced
today that its President and Chief Executive Officer, David Jin,
M.D., Ph.D., will co-chair a session, entitled “Cellular Therapy in
the Asia Pacific Region,” at the Transplantation & Cellular
Therapy (TCT) Meetings in Orlando, Florida. TCT Meetings are the
combined annual meetings of the American Society of Transplantation
and Cellular Therapy (ASTCT) and the Center for International Blood
and Marrow Transplant Research (CIBMTR).
Date: |
Thursday,
February 20, 2020 |
Time: |
1:00 PM - 4:00 PM |
Location: |
Orlando World Center Marriott – Exhibit Hall, Product Theater
Room 1 |
|
8701 World Center Drive, Orlando, Florida 32821 |
The session, "Cellular Therapy in the Asia Pacific Region," will
provide a venue to review and examine the current status and future
trends in cellular therapy (particularly immune effector cell
therapy, such as CAR-T), within Asia and the Pacific Rim
region. Invited speakers and panelists will present topics
about their expertise and experience on clinical protocols, outcome
analysis, regulatory affairs, standardization, and accreditation
related to cellular therapy during this session.
“We are honored to lead this session and panel discussion at the
industry renowned TCT Meetings, comprising the leading experts in a
rapidly evolving cellular therapy ecosystem in the Asia Pacific
region. We look forward to leveraging our respective experience and
capabilities in cell-based technologies and therapeutics. We will
contribute our scientific, regulatory, clinical and commercial
expertise to help empower high impact, transformative cell-based
technologies and their clinical applications,” stated David Jin,
M.D., Ph.D., CEO and President of Avalon GloboCare.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage,
leading CellTech bio-developer dedicated to advancing and
empowering innovative, transformative exosome technologies and
cellular therapeutics. Avalon also provides strategic advisory and
outsourcing services to facilitate and enhance its clients' growth,
development, as well as competitiveness in healthcare and CellTech
industry markets. Through its subsidiary structure with
unique integration of verticals from innovative R&D to
automated bioproduction and accelerated clinical development,
Avalon is establishing a leading role in the fields of in vitro
diagnostics (''liquid biopsy''), immune effector cell therapy
(including CAR-T/CAR-NK), and regenerative therapeutics. For more
information about Avalon GloboCare, please visit
www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking statements
provide current expectations of future events based on certain
assumptions and include any statement that does not directly relate
to any historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors as disclosed in our
filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite
3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Sep 2023 to Sep 2024